Drug Development Solutions Center, Drug Development Solutions Division, Sekisui Medical Co., Ltd., Tokai, Japan
Sekisui Medical Co., Ltd.
is focused on the advancement of new therapeutic research in human, animal and environmental science. To meet the challenges of increasing R&D costs, Sekisui Medical Co. is aggressively building onto its global contract research capabilities by aligning distinguished lineages of proven scientific expertise to accelerate R&D timelines, decrease costs and improve success rates via informed program decision-making. Sekisui Medical Co. has facilities around the world, including the Drug Development Solutions Center which began as the Tokai Research Institute of Daiichi Pure Chemicals Co., Ltd. in 1965 with the objective of contributing to the advancement and development of academic research through its radioisotope business. That business has grown and expanded into a broad range of pharmaceutical development research capabilities, from optimization of lead compounds to post-marketing surveillance of drugs.
In 2006, Daiichi Pure Chemicals Co., Ltd. was acquired by Sekisui Chemical Co., Ltd. Sekisui Medical Co., Ltd. was established in 2008 as part of the company's integration with Sekisui's Medical Division. Later the same year, the acquisition of XenoTech, LLC added focused expertise on biotransformation and preclinical development consulting to the broad range of pharmaceutical development services offered by Sekisui.
Our campus in Tokai, Japan is fully AAALAC accredited and features almost 150,000 ft2
, consisting of corporate and administrative offices and research laboratories on 8.42 acres. Laboratories include two clean rooms for cell culture, an animal care facility and a large variety of instrumentation to support both cold (non-radiolabeled) and hot (radiolabeled) compound investigations (including some radio-labeling services) for in vivo
and in vitro
ADME/Tox studies. We have over 25 years of experience in quantitative whole-body autoradiography (QWBA), and are one of the most trusted contract service providers in the world.
We strive to exceed the highest standards for quality in the process of drug development, inclusive of a globally experienced Quality Assurance System for implementation of GXP studies. We have advanced the introduction of new study systems such as those used for evaluating drug efficacy, toxicity and pharmacokinetics in humans to predict any potential risks as early as possible.
XenoTech was acquired by Sekisui Medical Co. Ltd in August of 2008. This alignment has allowed us to offer a comprehensive range of services to accelerate drug development, globally. Sekisui XenoTech is 1 of 11 subsidiaries that are a part of Sekisui America Corporation
, which represents Sekisui Chemical Group in North America and supports each Group company by providing reliable resources and assets. As the pioneering Japanese manufacturer in North America, Sekisui America Corporation has become an unstoppable force of diverse companies striving to achieve satisfaction in Service, Speed and Superiority while coexisting in harmony with our surroundings.